LabCorp's CRO unit Covance doubles down on cell, gene therapy offerings

LabCorp has unveiled a new suite of cell and gene therapy development offerings from Covance as it looks to get in on this burgeoning new trend. “These solutions are designed to reduce time and risk for sponsors at each phase and across the full continuum of their therapy development needs in one of the industry’s fastest-growing segments,” Covance, the CRO unit of diagnostics giant LabCorp, said in a statement. This follows the first CAR-T cell therapy approvals from Novartis and Gilead/Kite Pharma over the past few years in blood cancers, with CAR-T 2.0 also in the works (which could also target solid tumors) alongside the latent early work being done on gene editing and CRISPR, which could help across a range of diseases.